COVID-19 vaccine (Vaxzevria)

URI: https://gptkb.org/entity/COVID-19_vaccine_(Vaxzevria)

GPTKB entity

Statements (50)

Predicate	Object
gptkbp:instanceOf	vaccine
gptkbp:administeredBy	over 100 countries
gptkbp:age	adults 18 years and older
gptkbp:alsoKnownAs	gptkb:ChAdOx1_nCoV-19 gptkb:AstraZeneca_COVID-19_vaccine gptkb:AZD1222
gptkbp:approvedBy	gptkb:World_Health_Organization gptkb:European_Medicines_Agency December 2020
gptkbp:category	gptkb:essential_medicine_(WHO)
gptkbp:contains	gptkb:L-histidine gptkb:disodium_edetate_dihydrate gptkb:magnesium_chloride gptkb:polysorbate_80 sodium chloride ethanol sucrose genetic material encoding SARS-CoV-2 spike protein water for injections
gptkbp:contraindication	anaphylaxis to previous dose
gptkbp:countryOfOrigin	gptkb:United_Kingdom
gptkbp:developedBy	gptkb:University_of_Oxford gptkb:AstraZeneca
gptkbp:distributedBy	gptkb:COVAX
gptkbp:dosingSchedule	two doses
gptkbp:efficacyAgainstSevereDisease	high
gptkbp:efficacyAgainstSymptomaticCOVID-19	moderate to high
gptkbp:emergencyServices	granted in multiple countries
https://www.w3.org/2000/01/rdf-schema#label	COVID-19 vaccine (Vaxzevria)
gptkbp:includedIn	global vaccination campaigns
gptkbp:intervalBetweenDoses	4–12 weeks
gptkbp:manufacturer	multiple countries
gptkbp:notRecommendedFor	children under 18 people with history of severe allergic reaction to vaccine ingredients
gptkbp:packaging	multi-dose vials
gptkbp:regulates	varies by country
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:shelfLife	6 months at 2–8°C
gptkbp:sideEffect	fever fatigue headache muscle pain rare blood clotting events
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:technology	viral vector vaccine
gptkbp:vectorFor	gptkb:chimpanzee_adenovirus
gptkbp:WHO_EUL	listed
gptkbp:bfsParent	gptkb:AstraZeneca
gptkbp:bfsLayer	5